Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study

BACKGROUND: The phase II NIVOREN GETUG-AFU 26 study reported safety and efficacy of nivolumab in patients with metastatic clear cell renal cell carcinoma (m-ccRCC) in a ‘real-world setting’. We conducted a translational-research program to determine whether specific circulating immune-cell populatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Carril-Ajuria, Lucia, Desnoyer, Aude, Meylan, Maxime, Dalban, Cécile, Naigeon, Marie, Cassard, Lydie, Vano, Yann, Rioux-Leclercq, Nathalie, Chouaib, Salem, Beuselinck, Benoit, Chabaud, Sylvie, Barros-Monteiro, Janice, Bougoüin, Antoine, Lacroix, Guillaume, Colina-Moreno, Irelka, Tantot, Florence, Boselli, Lisa, De Oliveira, Caroline, Fridman, Wolf Herve, Escudier, Bernard, Sautes-Fridman, Catherine, Albiges, Laurence, Chaput-Gras, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157347/
https://www.ncbi.nlm.nih.gov/pubmed/35640928
http://dx.doi.org/10.1136/jitc-2022-004885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157347/
https://www.ncbi.nlm.nih.gov/pubmed/35640928
http://dx.doi.org/10.1136/jitc-2022-004885

Ejemplares similares